Abstract:The osteophilic and dual‐regulated alendronate‐gene lipoplexes are formulated via a thin‐film dispersion method and electrostatic interaction. The physical barriers are generated by alendronate on the lipoplexes surface, and the genetic signals are produced by antagomir inside the lipoplexes. More notably, alendronate and antagomir‐378a‐3p synergistically regulate osteoclastogenesis and bone resorption through a dual‐driven mechanism, thereby dramatically reversing bone loss. The pathogenesis of postmenopausal osteoporosis (PMOP) is mainly determined by the adhesion of osteoclasts to the bone matrix and the involvement of various molecules in bone resorption. The dual regulation strategy of the physical barriers of bone matrix and intracellular gene regulation generated by advanced biomaterials is a decent alternative for the treatment of PMOP. Herein, for the first time, it is identified that hsa‐miR‐378i/mmu‐miR‐378a‐3p are closely associated with PMOP. Then, an osteophilic and dual‐regulated alendronate‐gene lipoplex (antagomir@Aln‐Lipo), composed of medicative alendronate‐functionalized liposomal vehicle and encapsulated specific microRNAs is engineered, for bone‐targeting delivery of genes to achieve combined mitigation of bone loss. Alendronate targets hydroxyapatite in the bone matrix and occupies the adhesion site of osteoclasts, thus providing the "physical barriers". Antagomir is coupled precisely to specific endogenous microRNAs, thus providing the "genetic signals". These functionalized lipoplexes exhibited long‐term stability and good transfection efficiency. It is proven that antagomir@Aln‐Lipo could synergistically regulate osteoclastogenesis and bone resorption in vitro and in vivo. Furthermore, intravenous injection of antagomir@Aln‐Lipo efficiently reverses bone loss through a dual mechanism driven by alendronate and antagomir‐378a‐3p. In conclusion, the osteophilic and dual‐regulated antagomir@Aln‐Lipo offers a brand‐new bifunctional strategy for the precise treatment of PMOP.

A Delivery System Specifically Approaching Bone Resorption Surfaces to Facilitate Therapeutic Modulation of Micrornas in Osteoclasts.

A Bone-Resorption Surface-Targeting Nanoparticle to Deliver Anti-Mir214 for Osteoporosis Therapy.

Osteoblast-Targeting-Peptide Modified Nanoparticle for Sirna/Microrna Delivery

A Delivery System Targeting Bone Formation Surfaces to Facilitate RNAi-based Anabolic Therapy

AAV-mediated Delivery of Osteoblast/osteoclast-Regulating Mirnas for Osteoporosis Therapy

Osteoclast-targeted delivery of anti-miRNA oligonucleotides by red blood cell extracellular vesicles

Bi-directionally selective bone targeting delivery for anabolic and antiresorptive drugs: a novel combined therapy for osteoporosis?

AAV-mediated delivery of osteoblast/osteoclast-regulating miRNAs for osteoporosis therapy.

Construction of Multi‐Module RNA Nanoparticles Harboring miRNA, AIE, and CH6 Aptamer for Bone Targeting and Bone Anabolic Therapy

Bone-targeting PLGA derived lipid drug delivery system ameliorates bone loss in osteoporotic ovariectomized rats

Bone-targeted engineered bacterial extracellular vesicles delivering miRNA to treat osteoporosis

Current Progress On Microrna-Based Gene Delivery In The Treatment Of Osteoporosis And Osteoporotic Fracture

Suppression of Osteoclast Multinucleation Via a Posttranscriptional Regulation–based Spatiotemporally Selective Delivery System

Osteophilic and Dual‐Regulated Alendronate‐Gene Lipoplexes for Reversing Bone Loss

A Tetrahedral DNA Nanostructure-Mediated Mirna Inhibitor Delivery System: Type H Vessel-Related Bone Healing During Distraction Osteogenesis

Chemotactic recruitment of genetically engineered cell membrane-camouflaged metal-organic framework nanoparticles for ischemic osteonecrosis treatment

SDSSD Peptide Modified Polyvinylamine − A Novel Bone-Targeting RNA Delivery System

Cationic Glucan Dendrimer Gel-Mediated Local Delivery of Anti-OC-STAMP-siRNA for Treatment of Pathogenic Bone Resorption

Bioswitchable Delivery of microRNA by Framework Nucleic Acids: Application to Bone Regeneration

Liposomal α-cyperone targeting bone resorption surfaces suppresses osteoclast differentiation and osteoporosis progression via the PI3K/Akt axis

Osteoclast-derived Exosomal Mir-214-3p Inhibits Osteoblastic Bone Formation.